Organization | Heron Therapeutics

Heron Therapeutics Report issue

For profit Phase 2 Phase 3 Phase 4

Founded: Redwood City CA United States (1987)

Organization Overview

First Clinical Trial

2006

NCT00343460

First Marketed Drug

2016

granisetron (kytril)

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Heron Therapeutics | Heron Therapeutics, Inc. | HERON THERAPS INC

Active Ingredients

Marketed Drugs (4)

aprepitant (Emend) (2017)

granisetron (kytril) (2016)

levobupivacaine (chirocaine) (2021)

meloxicam (mobic) (2021)

Drugs in Phase 4 Trials (5)

acetaminophen (tylenol) (6 trials)

bupivacaine (Exparel) (21 trials)

granisetron (kytril) (4 trials)

ibuprofen (motrin) (6 trials)

levobupivacaine (chirocaine) (6 trials)

Drugs in Phase 3 Trials (5)

aprepitant (Emend) (3 trials)

celecoxib (celebrex) (1 trial)

ondansetron (zofran) (1 trial)

palonosetron (aloxi) (1 trial)

urea (2 trials)

Drugs in Phase 2 Trials (3)

epinephrine (levophed) (1 trial)

htx-009 (2 trials)

sodium chloride (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Agnosia (Phase 3)

Bunion (Phase 2)

Hernia, Inguinal (Phase 2)

Nausea (Phase 3)

Vomiting (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 27
# of Trial APIs: 13